NCT05238883 2025-11-21
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
HiFiBiO Therapeutics
BeOne Medicines
HiFiBiO Therapeutics
Novartis
Henan Cancer Hospital
BGI, China
Peking University Cancer Hospital & Institute